Antifungal Drugs: Technologies and Global Markets

  • ID: 4090191
  • Report
  • Region: Global
  • 272 Pages
  • BCC Research
15 % OFF
until Dec 31st 2018
1 of 6
The Global Market for Antifungal Drugs Should Reach $16.1 Billion by 2021, Growing at a CAGR of 4.2%

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Ferrer Internacional S.A.
  • Gilead Sciences, Inc.
  • MORE

Report Includes

  • An overview of the global market for antifungal drugs.
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Identification of new antifungal research, development, and drug applications.
  • Heavy focus on therapeutics in early development such as new molecular and biological entities from traditional pharmaceutical sources, naturally derived synthetic chemicals, and biological sources.
  • Information on over the counter (OTC) vs. prescription products.
  • Profiles of major players in the industry.

Report Scope

The aim of this report is to initially conduct a review of the antifungal drugs currently available, the issues facing the use of antifungal drugs and review some of the latest developments of new and innovative antifungal drugs, their technologies, and their intended clinical applications.

The key objective was also to conduct and provide an analysis of the market value, growth rates, market shares, market development as well as examining the market dynamics and market factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry, and the factors influencing the market shares of the major market suppliers as well as smaller indigenous manufactures in local markets. The emphasis of this report is to provide the reader with:

A detailed analysis of the revenues and forecasts for the global antifungal drugs market with a further more detailed analysis and forecast of the revenues for the global market sub-divided by major market sub-segments by geographic region and finally by selected country.
A detailed analysis of the global market share together with a further more detailed analysis of the market share by geographic regions and finally by selected country.

In addition this analysis provides a:

  • Detailed review of the current products, their indications and availability for all the market segments identified.
  • Profile of the individual markets sub-segments within the major market segments analyzed and the distinguishing features of each of the market sub-segments.
  • Review of the major market opportunities through the recognition of specific high-growth and emerging market opportunities.
  • Brief description of the historical development for each of the major market segments.
  • Profile of the leading suppliers of antifungal drugs together with related information about specific products.

The study will allow the reader to:

  • Evaluate the effect of strategic factors such as technology-driven change and industry consolidation for the antifungal drug market.
  • Investigate the current market dynamics that are driving change in the antifungal drug market.
  • Assess future growth opportunities in the antifungal drug market.
  • Review the main products in each sector and plan a product entry strategy in line with the strengths and weaknesses of the competition.
  • Utilize the report to help realize an individual company’s position in the market place and to provide insight into the future of the market and the opportunities that exist.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Ferrer Internacional S.A.
  • Gilead Sciences, Inc.
  • MORE

1: Introduction

  • Introduction To The Report
  • Reasons For Doing This Study
  • Scope
  • Methodology

2: Executive Summary

  • Market Segmentation

3: Introduction To The Global Antifungal Drug Market

  • Scope Of Applications: Human Healthcare
  • Primary Fungal Infections
  • Opportunistic Fungal Infections
  • Human Fungal Infections
  • Selection Of Statistical Data On Fungal Infections
  • Fungal Infection Of The Nails
  • Risk Factors For Developing Fungal Infections
  • Fungal Species That Cause Infection In Humans

4: Common Environmental Fungi

  • Molds And The Human Issues Associated With Them
  • Why Environmental Mold Is A Unique Problem
  • Health Risks Due To Environment Fungi And Mold
  • Environmental Molds

5: Antifungal Agents

  • Antifungal Agents
  • Classification Of Anti Fungal Agents
  • Systemic Antifungal Drugs
  • Azoles
  • Echinocandins
  • Antimetabolite: Flucytosine (5-Fc)
  • Other Systemic Antifungal Agents
  • Topical Antifungal Drugs
  • Others

6: Summary: Global Market For Antifungal Drugs

  • Introduction
  • Market Revenue Analysis

7: North American Market For Antifungal Drugs

  • Regulatory And Legislative Requirements
  • Market Dynamics
  • Market Revenue Analysis
  • Market Share Analysis

8: European Market For Antifungal Drugs

  • Regulatory And Legisative Requirements: Europe
  • The Russian Federation
  • Market Dynamics
  • Market Revenue Analysis
  • Market Share Analysis

9: Asia-Pacific Market For Antifungal Drugs

  • Japan
  • China
  • India
  • South Korea
  • Market Dynamics
  • Market Revenue Analysis
  • Market Share Analysis

10: Latin America Market For Antifungal Drugs

  • Brazil
  • Argentina
  • Mexico
  • Market Dynamics
  • Market Revenue Analysis
  • Market Share Analysis

11: Middle East/Africa Market For Antifungal Drugs

  • Introduction
  • South Africa
  • Saudi Arabia
  • Market Dynamics
  • Market Revenue Analysis
  • Market Share Analysis

12: Company Profiles

  • Manufacturers Of Prescription Pharmaceuticals
  • Otc Antifungal Manufacturers
  • Pharmaceutical Otc Market
  • Alternative Otc Manufacturers
  • Major Alternative Otc Manufacturer Profiles

13: Appendixes

  • Table 101 : Company Addresses And Contact Details

14: Government Regulatory Agencies And Professional Associations

  • Government Regulations
  • Food And Drug Administration (Fda)
  • Environmental Protection Agency (Epa)
  • United States Department Of Agriculture (Usda)
  • Food And Agricultural Organization Of The United Nations
  • Professional Associations

15: Commonly Used Acronyms Used In This Report

List Of Tables

Summary Table : Global Market For Antifungal Drugs, By Segment, Through 2021
Table 1 : Risk Factors Associated With Human Fungal Infections
Table 2 : Statistics Of The 10 Most Significant Invasive Fungal Infections
Table 3 : Risk Factors Associated With Human Fungal Infections
Table 4 : Epidemiology Of Common Fungal Diseases
Table 5 : Morphologic Features Of Fungi And Pseudofungi Infections Of Unusual Or Uncertain Etiology
Table 6 : Common Health Symptoms Based On Environmental Fungi And Molds
Table 7 : Risk Factors Associated With Environmental Fungi And Molds
Table 8 : Common Source Locations For Environmental Molds
Table 9 : Global Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 10 : Global Market For Antifungal Drugs, By Region, Through 2021
Table 11 : Global Market Share Analysis For Antifungal Drugs By Company, 2015
Table 12 : Patents For Amphotericin B And Estimated Expiry Dates
Table 13 : Approved Fluconazole Prescription Products
Table 14 : Patents For Itraconazole And Estimated Expiry Dates
Table 15 : Patents For Voriconazole And Estimated Expiry Dates
Table 16 : Approved Voriconazole Prescription Products
Table 17 : Patents For Posaconazole And Estimated Expiry Dates
Table 18 : Patents For Ketoconazole And Estimated Expiry Dates
Table 19 : Approved Miconazole Otc Products
Table 20 : International Brand Names For Clotrimazole
Table 21 : Approved Generic Prescription Verions Of Clotrimazole
Table 22 : Patents For Caspofungin And Estimated Expiry Dates
Table 23 : Patents For Micafungin And Estimated Expiry Dates
Table 24 : Patents For Anidulafungin And Estimated Expiry Dates
Table 25 : Global Market For Antifungal Drugs, By Segment, Through 2021
Table 26 : Global Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 27 : North America Market For Antifungal Drugs By Segment, Through 2021
Table 28 : North America Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 29 : Europe Market For Antifungal Drugs By Segment, Through 2021
Table 30 : Europe Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 31 : Asia-Pacific Market For Antifungal Drugs, By Segment, Through 2021
Table 32 : Asia-Pacific Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 33 : Latin America Market For Antifungal Drugs, By Segment, Through 2021
Table 34 : Latin America Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 35 : Middle East/Africa Market For Antifungal Drugs, By Segment, Through 2021
Table 36 : Middle East/Africa Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 37 : North America Market For Antifungal Drugs, By Segment, Through 2021
Table 38 : North America Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 39 : United States Market For Antifungal Drugs, By Segment, Through 2021
Table 40 : United States Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 41 : Canada Market For Antifungal Drugs, By Segment, Through 2021
Table 42 : Canada Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 43 : North America Market Share Analysis For Antifungal Drugs By Company, 2015
Table 44 : Europe Market For Antifungal Drugs By Segment, Through 2021
Table 45 : Europe Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 46 : France Market For Antifungal Drugs, By Segment, Through 2021
Table 47 : France Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 48 : Germany Market For Antifungal Drugs, By Segment, Through 2021
Table 49 : Germany Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 50 : Italy Market For Antifungal Drugs, By Segment, Through 2021
Table 51 : Italy Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 52 : Spain Market For Antifungal Drugs, By Segment, Through 2021
Table 53 : Spain Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 54 : United Kingdom Market For Antifungal Drugs, By Segment, Through 2021
Table 55 : United Kingdom Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 56 : Rest Of Europe Market For Antifungal Drugs, By Segment, Through 2021
Table 57 : Rest Of Europe Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 58 : Europe Market Share Analysis For Antifungal Drugs, 2015
Table 59 : Number Of Healthcare Institutions According To Ownership In China, 2010
Table 60 : Total Number Of Hospitals By Ranking China, 2010
Table 61 : Overview Of Healthcare In India
Table 62 : Asia-Pacific Market For Antifungal Drugs, By Segment, Through 2021
Table 63 : Asia-Pacific Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 64 : China Market For Antifungal Drugs, By Segment, Through 2021
Table 65 : China Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 66 : India Market For Antifungal Drugs, By Segment, Through 2021
Table 67 : India Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 68 : Japan Market For Antifungal Drugs, By Segment, Through 2021
Table 69 : Japan Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 70 : South Korea Market For Antifungal Drugs, By Segment, Through 2021
Table 71 : South Korea Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 72 : Taiwan Market For Antifungal Drugs, By Segment, Through 2021
Table 73 : Taiwan Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 74 : Other Asia-Pacific Markets For Antifungal Drugs, By Segment, Through 2021
Table 75 : Other Asia-Pacific Markets For Prescription Antifungal Drugs, By Segment, Through 2021
Table 76 : Asia-Pacific Market Share Analysis For Antifungal Drugs By Company, 2015
Table 77 : Latin America Market For Antifungal Drugs, By Segment, Through 2021
Table 78 : Latin America Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 79 : Argentina Market For Antifungal Drugs, By Segment, Through 2021
Table 80 : Argentina Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 81 : Brazil Market For Antifungal Drugs, By Segment, Through 2021
Table 82 : Brazil Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 83 : Chile Market For Antifungal Drugs, By Segment, Through 2021
Table 84 : Chile Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 85 : Mexico Market For Antifungal Drugs, By Segment, Through 2021
Table 86 : Mexico Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 87 : Rest Of Latin America (Rola) Market For Antifungal Drugs, By Segment, Through 2021
Table 88 : Rest Of Latin America (Rola) Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 89 : Latin America: Market Share Analysis Antifungal Drugs By Company, 2015
Table 90 : Middle East/Africa Market For Antifungal Drugs, By Segment, Through 2021
Table 91 : Middle East/Africa Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 92 : Middle East Market For Antifungal Drugs, By Segment, Through 2021
Table 93 : Middle East Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 94 : Africa Market For Antifungal Drugs, By Segment, Through 2021
Table 95 : Africa: Market For Prescription Antifungal Drugs, By Segment, Through 2021
Table 96 : Middle East/Africa Market Share For Antifungal Drugs, By Company, 2015
Table 97 : Annual Revenues Of Major Antifungal Drug (Merck)
Table 98 : Annual Revenues Of Major Antifungal Drug (Pfizer)
Table 99 : Major Human Otc Antifungal Manufacturers And Products
Table 100 : Commonly Available Alternative Antifungal Products
Table 101 : Company Addresses And Contact Details
Table 102 : Selected Antifungal Warning Letters For The Human Segment From The Fda To Manufacturers, 2005-2016

List Of Figures

Summary Figure A : Global Market For Antifungal Drugs, By Segment, 2015-2021
Summary Figure B : Global Market For Antifungal Drugs, By Segment, 2012-2021
Figure 1 : Global Burden Of Hiv-Related Cryptococcal Meningitis
Figure 2 : Global Market For Antifungal Drugs, By Region, 2015 - 2021
Figure 3 : Timeline Of Antifungal Drug Development
Figure 4 : Global Market For Antifungal Drugs, By Segment, 2012 - 2021
Figure 5 : Global Market Share For Antifungal Drugs, By Region, 2015
Figure 6 : North America Market For Antifungal Drugs, By Segment, 2012-2021
Figure 7 : Europe Market For Antifungal Drugs By Segment, 2012 - 2021
Figure 8 : Asia-Pacific Market For Antifungal Drugs By Segment, 2012 - 2021
Figure 9 : Latin America For Antifungal Drugs, By Segment, 2012 - 2021
Figure 10 : Middle East/Africa For Antifungal Drugs, By Segment, 2012-2021
Figure 11 : North America Market For Antifungal Drugs, By Segment, 2015-2021
Figure 12 : North America Market For Prescription Antifungal Drugs, By Individual Segment, 2015
Figure 13 : North America Market For Antifungal Drugs, By Individual Country, 2015
Figure 14 : Europe Market For Antifungal Drugs By Segment, 212-2021
Figure 15 : Europe Market For Prescription Antifungal Drugs, By Segment, 2015
Figure 16 : Europe Market For Antifungal Drugs By Individual Country, 2015
Figure 17 : Japan Drug Funding/Reimbursement Approval Process
Figure 18 : The Chinese Healthcare System
Figure 19 : Asia-Pacific Market For Antifungal Drugs, By Segment, 2012-2021
Figure 20 : Asia-Pacific Market For Prescription Antifungal Drugs, By Individual Segment, 2015
Figure 21 : Asia-Pacific Market For Antifungal Drugs, By Individual Country, 2015
Figure 22 : Argentina: Regulatory Drug Approval Process
Figure 23 : Latin America Market For Antifungal Drugs, By Segment, 2012-2021
Figure 24 : Latin America Market For Prescription Antifungal Drugs, By Individual Segment, 2015
Figure 25 : Latin America Market For Antifungal Drugs By Individual Country, 2015
Figure 26 : Current Structure Of The Healthcare Sectors In Saudi Arabia 2012
Figure 27 : Number Of Hospitals In Saudi, By Type, 2012
Figure 28 : Middle East/Africa Market For Antifungal Drugs, By Segment, 2012-2021
Figure 29 : Middle East/Africa: Market For Prescription Antifungal Drugs By Individual Segment, 2015
Figure 30 : Middle East/Africa Market For Antifungal Drugs, By Individual Region, 2015
Figure 31 : Progression Of Sales Of Jublia

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Ferrer Internacional S.A.
  • Gilead Sciences, Inc.
  • MORE

Methodology
The data collection and forecasting methods used in the preparation of this report are broadly divided into three methods.

Primary Data And Information Gathering

Data on individual product and company sales was gathered through interviews with manufacturers, end users, suppliers, distributors, and other relevant sources. These interviews typically include marketing managers, sales managers, distributor managers and owners, sales representatives and managers responsible for research and development (R&D). In addition, interviews were conducted with senior managers amongst competing companies to determine the strategic direction and focus on the technological advances being made and the sales and marketing policies being adopted.

Representatives of the leading suppliers included Ferrer Internacional S.A., Enzon Pharmaceuticals, Inc., Astellas Pharma Inc., Galderma Pharma SA Galderma SA, Gilead Sciences, Inc., Glenmark Pharmaceuticals Limited, Sigma-Tau Pharma-ceuticals, Inc., TEVA Pharmaceuticals Industries Ltd., Valeant Pharmaceuticals International, Inc. and Dartmouth Pharmaceuticals.

To ensure that the data derived from competitive interviews was accurate, the information was verified and corroborated by other interviews and by secondary sources, such as articles in the trade press, press releases, annual reports, online databases and government reports.

Secondary Data And Information Gathering

Information was obtained from numerous secondary data sources, including statistics provided by the CDC, WHO, FDA, United States Department of Agriculture (USDA), Environmental Protection Agency (EPA), The Infectious Disease Society of America (IDSA), Food and Agricultural Organization of the United Nations (FAOUN), the American Medical Association (AMA), the American Veterinary Medical Association (AVMA), the Infectious Diseases Society of America (IDSA), the American Phytopathological Society, the Pharmaceutical Research and Manufacturers of America (PhRMA), the Generic Pharmaceutical Association (GPhA), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Generic Medicines Association (EGA).

While these are believed to be the best secondary sources of data for various fungal diseases, the estimation of trends from this data is complicated by periodic changes in reporting and classification methods. In addition to the use of corporate annual and quarterly reports, data was obtained from security offering prospectuses, Forms 10-K and 10-Q, and product catalogs and price lists. This data was used along with other sources of data on company revenues (investment analysts’ reports, Reuter’s, Dun &Bradstreet, the CorpTech Directory, and personal communications from executives of various companies) to develop historic and current estimates of market revenues. Prices used in projections of market revenues are average prices paid by the end-user for the products and are derived.

Market Share Analysis And Market Forecast Prediction

Information and data, including estimates on market values, growth rates and market share data, were gathered through interviews with the competitors in the market. Great care was taken to avoid bias and untruths through developing a good relationship on the telephone and by using carefully worded questions that cross-verify themselves. The answers from the respondents were cross verified with answers from other employees and owners of the same company as well as from other manufacturers. Annual reports and the trade press also confirmed that the data collected were in the correct range.

The data gathered was incorporated into proprietary computer forecasting and market share analysis models. The forecast model was used to derive market estimates for future years. It incorporates a rate factor, which helps determine the speed with which the market develops, which is similar to that observed for markets for other medical products and is adjusted to match historic data for the market under analysis.

Analyst's Credentials

The author is an independent market analyst for the medical industry with a BSc and PhD in Biochemistry from the University of Liverpool and an MBA from Oxford Brookes University. The author has worked in the medical industry as a senior marketing executive for 20 years creating and implementing strategic business and marketing plans for major multinational medical device companies before establishing himself as an independent research analyst.

For the last 15 years the author has worked extensively in managing and conducting market research projects in key markets amongst healthcare professionals to determine market conditions, product attributes, issues and opinions. This data and information has been used to analyze specific product global market segments, create and implement strategic business and marketing plans for major multinational companies to launch new products and product line extensions, as well as re-marketing existing product lines.

The author has also acquired knowledge and experience with a wide range of software applications including windows office based applications including Microsoft Word, Excel, PowerPoint and Project, as well as more specific predictive analytical software such as SPSS, Stata and SAS, as a means of obtaining logistic regression, statistical variance analysis and mixed model analysis of market research data. This form of analysis has been used recently to prepare a variety of bespoke customized strategic marketing plans for individual clients in the biopharmaceutical and biotechnology industries.

Note: Product cover images may vary from those shown
5 of 6
  • Astellas Pharma Inc.
  • Enzon Pharmaceuticals, Inc.
  • Ferrer Internacional S.A.
  • Galderma Pharma SA Galderma SA
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals Limited
  • Inc. and Dartmouth Pharmaceuticals
  • Sigma-Tau Pharma-ceuticals, Inc.
  • TEVA Pharmaceuticals Industries Ltd.
  • Valeant Pharmaceuticals International
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll